SpringWorks Therapeutics (SWTX) Peer Comparison

$46.99

$0.00 (0.00%)

As on 02-Jul-2025 09:30EDT

Market cap

$3,541 Mln

Revenue (TTM)

$220 Mln

P/E Ratio

--

P/B Ratio

8.5

Div. Yield

0 %

Edit

	SpringWorks Therapeutics (SWTX)	Inozyme PharmaÂ Inc (INZY)
Market cap ($ Mln)	3,541	258
Revenue ($ Mln)	220	--
Net Profit ($ Mln)	-253.93	-106.72
Net Margin (%)	-115.60	--
RoE (%)	-53.46	-186.26
Price to Earnings	--	--
Price-To-Book	8.48	8.12

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	SpringWorks Therapeutics (SWTX)	Inozyme PharmaÂ Inc (INZY)
Operating Revenue	219.67	0.00
Cost of Revenue	14.88	0.67
Gross Profit	179.04	--
Operating Expenses	469.53	107.38
Operating Profit (EBIT)	-264.74	-107.38
Other Income	0.00	0.00
Profit before Tax	-253.93	-106.72
Provision for Tax	0.00	-0.01
Profit after Tax (Net Income)	-253.93	-106.72
Minority Interest	0.00	0.00
Consolidated Profit	0.00	0.00

Liabilities ($ Mln)

	SpringWorks Therapeutics (SWTX)	Inozyme PharmaÂ Inc (INZY)
Shareholder's Funds	417.40	31.80
Minority Interest	0.00	0.00
Non-Current Liabilities	5.69	20.59
Current Liabilities	82.27	42.78
Total Liabilities	587.28	123.18

Assets ($ Mln)

	SpringWorks Therapeutics (SWTX)	Inozyme PharmaÂ Inc (INZY)
Non-Current Assets	149.04	1.53
Current Assets	356.32	93.64
Total Assets	587.28	123.18
Total Debt*	7.39	46.95
Net Current Assets	274.05	50.86

Cashflow ($ Mln)

	SpringWorks Therapeutics (SWTX)	Inozyme PharmaÂ Inc (INZY)
Cash From Operating Activities	-175.60	-91.91
Cash Flow from Investing Activities	64.55	67.00
Cash from Financing Activities	4.76	11.40
Net Cash Inflow / Outflow	--	--

Ratios

Profitability Ratios

	SpringWorks Therapeutics (SWTX)	Inozyme PharmaÂ Inc (INZY)
ROCE (%)	-46.00	-69.93
ROE (%)	-53.46	-186.26
ROA (%)	-38.67	-65.21
EBIT Margin (%)	-120.52	--
Net Margin (%)	-115.60	--
Cash Profit Margin (%)	0.00	--

Growth Ratios

	SpringWorks Therapeutics (SWTX)	Inozyme PharmaÂ Inc (INZY)
Revenue Growth (%)	480.11	--
EBIT Growth (%)	26.49	-39.51
Net Profit Growth (%)	25.11	-38.39
EPS Growth (%)	31.55	-23.75
Book Value Growth (%)	-27.54	-74.29

Valuation Ratios

	SpringWorks Therapeutics (SWTX)	Inozyme PharmaÂ Inc (INZY)
Price / Earnings	-10.38	-1.71
Price / Book Value	5.57	3.01
Dividend Yield (%)	--	--
EV/EBITDA	-8.55	-1.04
Market Cap ($ Cr)	--	--

Solvency Ratios

	SpringWorks Therapeutics (SWTX)	Inozyme PharmaÂ Inc (INZY)
Debt to Equity	0.00	0.65
Short term debt to equity ratio	0.00	0.83
Current Ratio	4.33	2.19
Quick Ratio	4.18	2.19
Interest Coverage	-253.44	-17.92

Operating Efficiency Ratios

	SpringWorks Therapeutics (SWTX)	Inozyme PharmaÂ Inc (INZY)
Debtors to sales (%)	18.37	--
Asset Turnover	0.33	0.00
Receivable days	49.73	--
Inventory Days	193.76	--
Payable days	285.86	--
Cash Conversion Cycle	-42.37	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly